Abemaciclib With Letrozole in Recurrent or Persistent Endometrial Cancer
This research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial cancer.
The drugs involved in this study are:
- Abemaciclib (also known as Verzenio(TM))
- Letrozole (also known as Femara(R))
A Phase 2 Study of Abemaciclib with Letrozole in Recurrent or Persistent Endometrial Cancer
- ClinicalTrials.gov Identifier: NCT03675893
- Protocol Number: 18-301
- Principal Investigator: Meghan Shea
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required